The global Omega-3 market is poised for significant expansion, growing from USD 5,785.1 million in 2025 to USD 13,323.1 million by 2035 at a CAGR of 8.7%. Demand is surging due to rising consumer awareness of Omega-3’s health benefits—ranging from cardiovascular wellness and cognitive support to anti-inflammatory effects. Pharma-grade formulations, infant nutrition, and aging population health are emerging as major growth drivers.

Unlock Key Market Trends: Get Your Sample Report

Market Trends Highlighted

• Pharmaceutical Transformation: Omega-3 is moving from the supplement shelf to prescription drug status in markets like the U.S., where highly purified formulations are addressing heart and neurological health.
• Premium Infant Formula: In China, DHA fortification in infant formula is surging, bolstered by tighter national regulations and an expanding middle class.
• Cognitive Health Focus: Japan’s aging population is turning to DHA and EPA for brain health, fueling innovation in bioavailable and functional Omega-3 formats.
• Algae-Based Omega-3 Rising: Plant-based and algal sources are gaining traction over traditional fish oils, aligning with clean-label and sustainability trends.
• Advanced Delivery Systems: Emulsified Omega-3, softgels, and phospholipid-bound forms are becoming more prevalent to increase absorption and efficacy.
• Regulatory Momentum: Supportive frameworks like the U.S. FDA, China’s GB standards, and Japan’s FOSHU/FFC are accelerating high-quality Omega-3 innovation and market access.

Key Takeaways of the Report

• The Omega-3 market will grow at a CAGR of 8.7% between 2025 and 2035, reaching over USD 13.3 billion by the end of the forecast period.
• Pharmaceutical applications are leading innovation, especially in cardiovascular and neuroprotective therapeutics.
• Infant nutrition and elderly health are the two key demographics propelling DHA-based Omega-3 consumption globally.
• Technological advancements in formulation and delivery—like microencapsulation, emulsions, and high-purity concentrates—are shaping product development.
• Demand for plant-based and sustainably sourced Omega-3 is on the rise, opening new opportunities for algal DHA and vegan supplements.

Regional Market Outlook

United States – Pharma-Grade Omega-3 Gaining Momentum
CAGR: 4.2%
The U.S. Omega-3 market is rapidly transitioning toward high-dose, pharmaceutical-grade EPA and DHA, used predominantly in cardiovascular treatments. Driven by FDA-approved products like Vascepa, companies are developing ultrarefined formulations with high bioavailability. Prescription Omega-3s, particularly those targeting triglyceride levels and neurodegenerative conditions, are increasingly reimbursable and supported by clinical trials.

China – DHA Fortification in Infant Nutrition Leads Growth
CAGR: 5.1%
China’s Omega-3 demand is accelerating due to the premiumization of infant formula, with DHA now a core ingredient supported by strict regulatory standards. Major investments in algal DHA production are helping companies like Cargill and Corbion capture a rapidly growing market segment. Cross-border e-commerce and rising disposable income further amplify demand for high-quality Omega-3 supplements.

Japan – Omega-3 for Brain Health in Aging Demographic
CAGR: 2.5%
Japan’s Omega-3 market is increasingly focused on cognitive longevity. With dementia on the rise, products featuring DHA and phospholipid-bound Omega-3s are gaining traction. The country’s FOSHU and FFC systems encourage scientific claims, allowing brands to launch functional foods and beverages tailored to senior citizens seeking memory and cognitive support.

Competition Outlook

The global Omega-3 market is witnessing intense competition and innovation as companies race to meet the demands of pharma, nutrition, and wellness consumers. Leading players such as DSM, KD Pharma, BASF, Cargill, Corbion, and Nissui are expanding their Omega-3 portfolios through:

Leading Manufacturers

• DSM Nutritional Products
• BASF SE
• Cargill, Inc.
• Corbion N.V.
• Omega Protein Corporation
• Epax Norway AS
• GC Rieber Oils
• Croda International Plc
• Archer Daniels Midland Company (ADM)
• Nordic Naturals
• KD Pharma Group
• Novonesis Group
• Golden Omega S.A